论文部分内容阅读
本文研究了Ｇｒａｖｅｓ病（ＧＤ）患者在抗甲状腺药物（ＡＴＤ）治疗前、后血清甲状腺刺激抗体（ＴＳＡｂ）和ＴＳＨ结合抑制免疫球蛋白（ＴＢＩＩ）的变化，发现治疗前ＴＳＡｂ和ＴＢＩＩ的检出率分别为９１．７％和７９．２％，治疗后两抗体的活性及阳性率均显著下降，表明抗甲状腺药可改善ＧＤ患者的免疫异常。ＴＳＡｂ和ＴＢＩＩ活性不相关，提示ＴＳＨ受体抗体（ＴＲＡｂ）具有异质性。ＴＳＡｂ和ＴＢＩＩ活性与血清甲状腺激素水平无相关关系，说明体外测定的ＴＳＡｂ或／和ＴＢＩＩ活性并不能完全反映甲亢的严重程度。
In this paper, the changes of serum thyroid stimulating antibody (TSAb) and TSH binding to immunoglobulin (TBII) in patients with Graves’ disease (GD) before and after antithyroid drug treatment (ATD) were studied. The detection rates of TSAb and TBII before treatment Respectively 91.7% and 79.2%. After treatment, the activity and the positive rate of the two antibodies were significantly decreased, indicating that anti-thyroid drugs can improve the immune abnormalities in patients with GD. TSAb and TBII activity is not related, suggesting TSH receptor antibody (TRAb) has heterogeneity. TSAb and TBII activity and serum thyroid hormone levels have no correlation, indicating that in vitro determination of TSAb or / and TBII activity does not fully reflect the severity of hyperthyroidism.